Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study.

Coutre, Steven E; Barnett, Christopher; Osiyemi, Olayemi; Hoda, Daanish; Ramgopal, Moti; Fort, Alexander C; Qaqish, Roula; Hu, Yiran; Ninomoto, Joi; Alami, Negar N; Styles, Lori; Treon, Steven P

Coutre, Steven E; Barnett, Christopher; Osiyemi, Olayemi; Hoda, Daanish; Ramgopal, Moti; Fort, Alexander C; Qaqish, Roula; Hu, Yiran; Ninomoto, Joi; Alami, Negar N; Styles, Lori; Treon, Steven P.

Afiliação

Coutre SE; Stanford Cancer Center, Stanford University School of Medicine, Stanford, California, USA.
Barnett C; MedStar Washington Hospital Center, Washington, District of Columbia, USA.
Osiyemi O; University of California, San Francisco, San Francisco, California, USA.
Hoda D; Triple O Research Institute, West Palm Beach, Florida, USA.
Ramgopal M; Intermountain Healthcare, Salt Lake City, Utah, USA.
Fort AC; Midway Immunology and Research Center, Fort Pierce, Florida, USA.
Qaqish R; University of Miami Miller School of Medicine, Miami, Florida, USA.
Hu Y; AbbVie, North Chicago, Illinois, USA.
Ninomoto J; AbbVie, North Chicago, Illinois, USA.
Alami NN; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California, USA.
Styles L; AbbVie, North Chicago, Illinois, USA.
Treon SP; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California, USA.

Open Forum Infect Dis ; 9(5): ofac104, 2022 May.

Article em En | MEDLINE | ID: mdl-35493119

Palavras-chave

COVID-19; SARS-CoV-2; ibrutinib; lung injury; respiratory failure

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google